Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing antibody titres in SARS-CoV-2 infections
Eric H. Y. Lau, Owen TY Tsang, David S.C. Hui, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 358

Showing 1-25 of 358 citing articles:

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Xianding Deng, Miguel Garcia-Knight, Mir M. Khalid, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3426-3437.e8
Open Access | Times Cited: 513
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Lisa Müller, Marcel Andrée, Wiebke Moskorz, et al.
Clinical Infectious Diseases (2021) Vol. 73, Iss. 11, pp. 2065-2072
Open Access | Times Cited: 474
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer, Frances Ayres, Tandile Hermanus, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 283
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Brian J. Ward, Philipe Gobeil, Annie Séguin, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 1071-1078
Open Access | Times Cited: 269
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3452-3466.e18
Open Access | Times Cited: 258
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation
Xianding Deng, Miguel Garcia-Knight, Mir M. Khalid, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 238
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
Andrew G. Letizia, Yongchao Ge, Sindhu Vangeti, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 7, pp. 712-720
Open Access | Times Cited: 162
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Michael J. Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances (2021) Vol. 7, Iss. 31
Open Access | Times Cited: 139
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
Natalie Yan‐Lin Pang, Alexander Shao‐Rong Pang, Vincent Chow, et al.
Military Medical Research (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Controlling the pandemic during the SARS-CoV-2 vaccination rollout
João Viana, Christiaan H. van Dorp, Ana Nunes, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 126
SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
Carolyn A. Cohen, Athena P. Y. Li, Asmaa Hachim, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 121
Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality
Mehul D. Patel, Erik Rosenstrom, Julie S. Ivy, et al.
JAMA Network Open (2021) Vol. 4, Iss. 6, pp. e2110782-e2110782
Open Access | Times Cited: 109
Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features
Anastasia Gangaev, Steven L. C. Ketelaars, Olga I. Isaeva, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 108
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Yang Yang, Minghui Yang, Yun Peng, et al.
Nature Microbiology (2022) Vol. 7, Iss. 3, pp. 423-433
Open Access | Times Cited: 104
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, et al.
Diagnostic Microbiology and Infectious Disease (2022) Vol. 103, Iss. 1, pp. 115659-115659
Open Access | Times Cited: 73
Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4 + T Cell Responses
Eun-Ha Kim, Quyen Thi Nguyen, Mark Anthony B. Casel, et al.
Journal of Virology (2022) Vol. 96, Iss. 6
Open Access | Times Cited: 68
Comparative Analysis of Virology and Pathogenesis of SARS-CoV-2 and HIV Infections: Implications for Public Health and Treatment Strategies
David Francis Olebo, Matthew Chibunna Igwe
Infection and Drug Resistance (2025) Vol. Volume 18, pp. 269-283
Open Access | Times Cited: 1
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
Tom G. Caniels, Ilja Bontjer, Karlijn van der Straten, et al.
Science Advances (2021) Vol. 7, Iss. 36
Open Access | Times Cited: 99
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
Julien Favresse, Constant Gillot, Laura Di Chiaro, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1364-1364
Open Access | Times Cited: 90
Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines
Jiping Liu, Junbang Wang, Jinfang Xu, et al.
Cell Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 85
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
Eric H. Y. Lau, David S.C. Hui, Owen TY Tsang, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101174-101174
Open Access | Times Cited: 78
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Gregory Milne, Thomas Hames, Chris J. Scotton, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1450-1466
Open Access | Times Cited: 78
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
Irit Avivi, Roi Balaban, Tamir Shragai, et al.
British Journal of Haematology (2021) Vol. 195, Iss. 2, pp. 186-193
Open Access | Times Cited: 71
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection
Lin Yao, Guolin Wang, Yuan Shen, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 4, pp. 586-594
Open Access | Times Cited: 70
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Ali Hamady, JinJu Lee, Zuzanna Loboda
Infection (2021) Vol. 50, Iss. 1, pp. 11-25
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top